Intravitreal Bevacizumab and Ranibizumab for Choroidal Neovascularization Secondary to Endogenous Endophthalmitis

Fecko, Alice M; Ho, Lawrence Y.; Walsh, Mark K.; Williams, George A.

doi:10.1097/icb.0b013e3181e1ed1e

Cited by 2 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is unknown what effect the actual microbe may have had on the vascular membrane. It is well known, however, that chronic inflammatory diseases 12 may be complicated by the development of choroidal neovascularization and even infectious conditions, such as endogenous endophthalmitis, [13][14][15] can lead to neovascularization, so the mechanism of regression in this case series is unclear.…”

Section: Discussionmentioning

confidence: 99%

Involution of Neovascular Age-Related Macular Degeneration After Endophthalmitis

Kokame

Yannuzzi

Shantha

et al. 2021

RETINAL Cases &Amp; Brief Reports

View full text Add to dashboard Cite

Purpose: To report patients who demonstrated an alteration in the clinical and optical coherence tomography features of neovascular age-related macular degeneration after resolution of endophthalmitis.Methods: Retrospective case series of the subsequent changes in the macula and need for anti-vascular endothelial growth factor therapy in patients with neovascular age-related macular degeneration who developed endophthalmitis after intravitreal injection.Results: The study included seven eyes of seven patients with follow-up ranging between 3 months and 11 years. The vitreous cultures (n = 7) before intravitreal antibiotic injection were the following: culture-negative (4) and coagulase-negative Staphylococcus (3). Initial treatment included vitreous tap and injection (4) and pars plana vitrectomy (3). In 5/7 eyes, the optical coherence tomography showed resolution of subretinal fluid and serous pigment epithelial detachment, and there was no additional anti-vascular endothelial growth factor treatment administered.Conclusion: After successful treatment of endophthalmitis in patients with neovascular age-related macular degeneration, there was relative involution of the maculopathy and reduced anti-vascular endothelial growth factor treatment burden in this series.

show abstract

Section: Discussionmentioning

confidence: 99%

Involution of Neovascular Age-Related Macular Degeneration After Endophthalmitis

Kokame

Yannuzzi

Shantha

et al. 2021

RETINAL Cases &Amp; Brief Reports

View full text Add to dashboard Cite

show abstract

The Role of Steroids and NSAIDs in Prevention and Treatment of Postsurgical Cystoid Macular Edema

Grzybowski

Kanclerz²

2019

CPD

View full text Add to dashboard Cite

Background: Pseudophakic cystoid macular edema (PCME) remains one of the most common visionthreatening complication of phacoemulsification cataract surgery (PCS). Pharmacological therapy is the current mainstay of both prophylaxis, and treatment of PCME in patients undergoing PCS. We aimed to review pharmacological treatment options for PCME, which primarily include topical steroids, topical nonsteroidal antiinflammatory drugs (NSAIDS), periocular and intravitreal steroids, as well as anti-vascular endothelial growth factor therapy. Methods: The PubMed and Web Of Science web platforms were used to find relevant studies using the following keywords: cataract surgery, phacoemulsification, cystoid macular edema, and pseudophakic cystoid macular edema. Of articles retrieved by this method, all publications in English and abstracts of non-English publications were reviewed. Other studies were also considered as a potential source of information when referenced in relevant articles. The search revealed 193 publications. Finally 82 articles dated from 1974 to 2018 were assessed as significant and analyzed. Results: Based on the current literature, we found that corticosteroids remain the mainstay of PCME prophylaxis in uncomplicated cataract surgery, while it is still unclear if NSAID can offer additional benefits. In patients at risk for PCME development, periocular subconjunctival injection of triamcinolone acetonide may prevent PCME development. For PCME treatment the authors recommend a stepwise therapy: initial topical steroids and adjuvant NSAIDs, followed by additional posterior sub-Tenon or retrobulbar corticosteroids in moderate PCME, and intravitreal corticosteroids in recalcitrant PCME. Intravitreal anti-vascular endothelial growth factor agents may be considered in patients unresponsive to steroid therapy at risk of elevated intraocular pressure, and with comorbid macular disease. Conclusion: Therapy with topical corticosteroids and NSAIDs is the mainstay of PCME prophylaxis and treatment, however, periocular and intravitreal steroids should be considered in refractory cases.

show abstract

Intravitreal Bevacizumab and Ranibizumab for Choroidal Neovascularization Secondary to Endogenous Endophthalmitis

Abstract: Choroidal neovascularization secondary to endogenous endophthalmitis responds to anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab.

Cited by 2 publications

References 9 publications

Involution of Neovascular Age-Related Macular Degeneration After Endophthalmitis

Involution of Neovascular Age-Related Macular Degeneration After Endophthalmitis

The Role of Steroids and NSAIDs in Prevention and Treatment of Postsurgical Cystoid Macular Edema

Contact Info

Product

Resources

About